Burdick Kenneth A sold $5.8M of LFST

Burdick Kenneth A sold 500,000 shares of LifeStance Health Group, Inc. (LFST) at $11.51 ($5.76M total) on 2026-08-11.

Original reporting
SEC EDGAR · Burdick Kenneth A
Published Aug 13, 2026, 9:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 9:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LFST
Neutral
medium confidence
Mentioned
$LFST
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LFSTNeutralLow
01

Why it matters

A director open-market sale of 500,000 shares at $11.51 provides a datapoint on insider liquidity, but it does not include guidance, operational updates, or regulatory/legal developments.

02

Market read

Traders may note insider selling, but the filing alone is unlikely to drive a sustained repricing without additional company-specific catalysts.

03

What to watch

Without context on total holdings, prior sale cadence, and whether other insiders also sold, the signal strength is weak.

Relevance 6/10Novelty 3/10Timing: filed after-hours on 2026-08-13, reflecting the 2026-08-11 sale

Background

The article is a SEC Form 4 insider transaction disclosure for LifeStance Health Group, Inc.

Company-level read

Ticker impact

$LFSTNeutralMedium confidence
Context

LifeStance Health Group director Kenneth Burdick sold 500,000 shares in an open-market transaction for about $5.76M.

Expected impact

Limited near-term impact; any reaction is likely noise unless paired with other disclosures.

Evidence & confidence

Form 4 insider sales are common and often non-informational; the filing provides transaction size and price but no accompanying company-specific news.

Market effects

No clear sector read-through from a single director open-market sale.

None.

None.

Counterpoint

The absence of a disclosed 10b5-1 plan could be interpreted as more discretionary selling, but insider sales still frequently reflect diversification or liquidity needs.

Key entities

  • LifeStance Health Group, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Kenneth Burdick

    Director who sold 500,000 shares on 2026-08-11.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LFSTMed

BMO raises Lifestance Health stock price target on strong results

BMO Capital raised its price target on Lifestance Health (LFST) to $16.00, citing strong Q3 results. Revenue beat estimates by 5.6%, and EBITDA exceeded by 23.6%. The company raised its full-year outlook, but expects a sequential EBITDA decline due to reinvestment. LFST trades at $13.43 with a $5.1B market cap. The company also announced Q3 2026 earnings, surpassing expectations with a 25% revenue increase.

$LFSTMed

What LifeStance Health Group (LFST) Said on Its Q3 Earnings Call

LifeStance Health Group (LFST) forecasted Q4 revenue of $446M-$466M and adjusted EBITDA of $56M-$64M. The company expects a 1-2% reduction in 2027 revenue growth due to a new electronic health record system. LifeStance expanded specialty services, including TMS and SPRAVATO, and plans to continue acquisitions and center openings. Management expects specialty services revenue to reach $70M this year, up from $50M in 2025.

$LFSTMed

LifeStance Health Group Inc (LFST) (Q3 2026) Earnings Call Highlights: Revenue Jumps 25%

LifeStance Health (LFST) reported 25% revenue growth in Q3 2026. The company expects EHR implementation to reduce 2027 revenue growth by 1-2% and cost $20-30M. Clinician retention is stable, but new clinician retention is low. Q4 adjusted EBITDA guidance suggests a sequential decline due to planned investments. Specialty services, including Spravato, are growing but face variable payer reimbursement. Management remains optimistic about long-term margin expansion and clinician growth.

$LFSTHighAI 8/10

LifeStance (LFST) Q3 2026 Earnings Call Transcript

LifeStance (LFST) reported Q3 2026 revenue growth of 25% to $456M, driven by increased visit volumes and higher revenue per visit. The company expanded its clinician base by 11% and opened 8 new centers. It also raised full-year revenue guidance to $1.741B-$1.761B. LifeStance highlighted strong results in specialty services for treatment-resistant depression and plans to invest in strategic priorities. The company expects temporary revenue growth impact in 2027 due to EHR implementation.

$LFSTMed

LifeStance Health: Q3 Earnings Snapshot

LifeStance Health Group Inc. (LFST) reported Q3 net income of $22.4M, or 6 cents per share, beating estimates. Revenue was $455.9M, also exceeding forecasts. The company expects Q4 revenue of $446M-$466M and full-year revenue of $1.74B-$1.76B.